Another humbling scientific failure to improve mild/moderate Alzheimer’s Disease in a large, phase 3 clinical trial. Merck’s BACE1-inhibitor: reduced amyloid breakdown product by up to 80%, but failed to improve mental outcomes or any other clinical endpoint.

See the source article by following the link below:
Another humbling scientific failure to improve mild/moderate Alzheimer’s Disease in a large, phase 3 clinical trial. Merck’s BACE1-inhibitor: reduced amyloid breakdown product by up to 80%, but failed to improve mental outcomes or any other clinical endpoint.